These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 10858046)
1. [Importance of thalidomide in the treatment of cancer]. Bay JO; Tournilhac O Bull Cancer; 2000 Apr; 87(4):301-2. PubMed ID: 10858046 [No Abstract] [Full Text] [Related]
2. [Role of thalidomide in the treatment of multiple myeloma]. Mikala G; Jákó J; Vályi-Nagy I Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633 [TBL] [Abstract][Full Text] [Related]
4. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide, a thalidomide derivative, shows promise in various applications. Oestreicher P ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579 [No Abstract] [Full Text] [Related]
6. Role of thalidomide in previously untreated patients with multiple myeloma. Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ; Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
8. [Thalidomide with or without dexamethasone for refractory multiple myeloma]. Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Therapie; 2002; 57(6):524-9. PubMed ID: 12666259 [TBL] [Abstract][Full Text] [Related]
9. Thalidomide: when everything old is new again. Nirenberg A Clin J Oncol Nurs; 2001; 5(1):15-8. PubMed ID: 11899395 [TBL] [Abstract][Full Text] [Related]
10. Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma. Fenk R; Hoyer B; Steidl U; Kondakci M; Graef T; Heuk R; Ruf L; Strupp C; Neumann F; Rohr UP; Hildebrandt B; Haas R; Kobbe G Leukemia; 2005 Jan; 19(1):156-9. PubMed ID: 15510204 [No Abstract] [Full Text] [Related]
11. Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. Corso A; Mangiacavalli S; Barbarano L; Montalbetti L; Mazzone A; Fava S; Varettoni M; Zappasodi P; Morra E; Lazzarino M Leuk Res; 2008 Jul; 32(7):1085-90. PubMed ID: 18096226 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide in the treatment of multiple myeloma. Kastritis E; Dimopoulos MA Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713 [TBL] [Abstract][Full Text] [Related]
14. The thalidomide saga. Melchert M; List A Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076 [TBL] [Abstract][Full Text] [Related]